(Q46027197)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Myeloid cells as effector cells for monoclonal antibody therapy of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Tom O'Toole

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Marjolein van Egmond

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

publication date

27 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

28-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

Antibody therapy of cancer

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Monoclonal antibodies: versatile platforms for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Properties of mouse and human IgG receptors and their contribution to disease models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Fc receptors are required in passive and active immunity to melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc RI and Fc RIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Innate or adaptive immunity? The example of natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Macrophage plasticity and polarization in tissue repair and remodelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Exploring the full spectrum of macrophage activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

High macrophage infiltration along the tumor front correlates with improved survival in colon cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Distinct role of macrophages in different tumor microenvironments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Macrophage regulation of tumor responses to anticancer therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Using macrophage activation to augment immunotherapy of established tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

In vivo tumouricidal effects of LAD-1 monoclonal antibody on murine RL-male-1 lymphoma mediated by enhanced phagocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Flow cytometry and cell sorting: the next generation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Review of advanced imaging techniques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Ligand binding but undetected functional response of FcR after their capture by T cells via trogocytosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophil function: from mechanisms to disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The intriguing role of polymorphonuclear neutrophils in antitumor reactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophils in antibody-based immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Antibodies, Fc receptors and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Activated neutrophils as effector cells for bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Immunotherapeutic perspective for bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Clinical experience with CD64-directed immunotherapy. An overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Immunoglobulin A: A next generation of therapeutic antibodies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Serum-free production and purification of chimeric IgA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophil extracellular traps kill bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Granzymes A and B are not expressed in human neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Granzyme A: an additional weapon of human polymorphonuclear neutrophils (PMNs) in innate immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Human neutrophils lack granzyme A, granzyme B, and perforin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Autophagy fights disease through cellular self-digestion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The end of autophagic cell death?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophils in the activation and regulation of innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Evidence for a cross-talk between human neutrophils and Th17 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Close encounters of neutrophils and DCs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

Complement function in mAb-mediated cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.020

10.1016/J.YMETH.2013.06.020

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23811299%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference